Document Detail


What is potent acid inhibition, and how can it be achieved?
MedLine Citation:
PMID:  16335854     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The clinical response to antisecretory treatment correlates directly with the degree of inhibition of acid secretion achieved. Acid inhibition able to maintain the intragastric pH at a value greater than 4 for at least 16 h/day seems to heal even the most refractory acid-related diseases. It has also been shown that the degree of inhibition of acid secretion in response to antisecretory treatment depends on the genetic characteristics of the patient and on the presence of Helicobacter pylori infection. A possible definition of potent (or profound) acid inhibition is, therefore, the achievement of the aforementioned level of control of acid secretion regardless of patient characteristics or of the presence of H. pylori infection. Antisecretory drugs differ in their ability to reach potent acid inhibition. As far as the comparative efficacy of different drugs for inhibiting acid secretion is concerned, proton pump inhibitors are more efficient in inhibiting gastric acid secretion than histamine (H2) receptor antagonists. Among the different proton pump inhibitors, esomeprazole 40 mg/day exhibits greater antisecretory potency than the others at standard doses. Rabeprazole 20 mg/day and lansoprazole 30 mg/day exhibit a more rapid onset of action than omeprazole 20 mg/day or pantoprazole 40 mg/day.
Authors:
Xavier Calvet; Fernando Gomollón
Related Documents :
14992434 - Gastric electrical stimulation does not significantly affect canine gastric acid secret...
7910794 - Cholecystokinin type a receptors mediate intestinal fat-induced inhibition of acid secr...
12044824 - S-propyl cysteine reduces the secretion of apolipoprotein b100 and triacylglycerol by h...
8292984 - Effect of h-egf and h-egf 1-48 on histamine-stimulated gastric acid secretion in rats a...
993224 - Poly(glycolic acid) sutures in canine vascular anastomoses.
15522824 - Translocation of phospholipase a2 to membranes by oxidized ldl and hydroxyoctadecadieno...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  65 Suppl 1     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2005  
Date Detail:
Created Date:  2005-12-12     Completed Date:  2005-12-23     Revised Date:  2013-06-04    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  13-23     Citation Subset:  IM    
Affiliation:
Digestive Diseases Unit, Sabadell Hospital, Parc Taulí University Institute, Autonomous University of Barcelona, Spain. xcalvet@cspt.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Anti-Ulcer Agents / administration & dosage*
Benzimidazoles / administration & dosage
Clinical Trials as Topic
Esomeprazole Sodium
Gastric Acid / secretion*
Humans
Omeprazole / administration & dosage,  analogs & derivatives
Peptic Ulcer / drug therapy*
Proton Pumps / antagonists & inhibitors*
Sulfoxides / administration & dosage
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Benzimidazoles; 0/Proton Pumps; 0/Sulfoxides; 103577-45-3/lansoprazole; 32828355LL/rabeprazole; 73590-58-6/Omeprazole; D8TST4O562/pantoprazole; L2C9GWQ43H/Esomeprazole Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A pharmacological approach to gastric acid inhibition.
Next Document:  Optimising acid inhibition treatment.